First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.

CONCLUSION: The overall CSR for GERD patients was similar at days 1-7 for both the dexlansoprazole and esomeprazole groups, although a higher incidence of CSR was observed on day 3 in female patients who received a single dose of dexlansoprazole.
PMID: 29307999 [PubMed - in process]

Source: World Journal of Gastroenterology : WJG - December 21, 2017 Category: Gastroenterology Authors: Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK, Taiwan Acid-Related Disease Study Group Tags: World J Gastroenterol Source Type: research